Seer (NASDAQ:SEER) Shares Down 0.5% – Should You Sell?

Seer, Inc. (NASDAQ:SEER) shares traded down 0.5% during mid-day trading on Monday . The company traded as low as $1.79 and last traded at $1.81. 218,058 shares changed hands during trading, an increase of 85% from the average session volume of 117,801 shares. The stock had previously closed at $1.82.

Analysts Set New Price Targets

SEER has been the subject of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Seer in a report on Thursday, January 22nd. Wall Street Zen raised shares of Seer to a “hold” rating in a research report on Saturday, December 13th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Seer presently has an average rating of “Sell”.

Seer Trading Down 0.5%

The stock has a market capitalization of $100.98 million, a PE ratio of -1.33 and a beta of 1.63. The firm has a 50-day moving average price of $1.87 and a 200-day moving average price of $2.04.

Seer (NASDAQ:SEER) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.01. The company had revenue of $4.12 million during the quarter, compared to analyst estimates of $4.00 million. Seer had a negative net margin of 484.51% and a negative return on equity of 25.88%. Sell-side analysts expect that Seer, Inc. will post -1.42 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Omid Farokhzad sold 33,838 shares of Seer stock in a transaction that occurred on Wednesday, November 19th. The shares were sold at an average price of $1.97, for a total value of $66,660.86. Following the sale, the chief executive officer owned 1,238,230 shares of the company’s stock, valued at approximately $2,439,313.10. The trade was a 2.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 11.28% of the stock is currently owned by insiders.

Institutional Trading of Seer

A number of large investors have recently bought and sold shares of the company. Susquehanna International Group LLP lifted its position in shares of Seer by 22.8% during the 3rd quarter. Susquehanna International Group LLP now owns 123,447 shares of the company’s stock valued at $268,000 after buying an additional 22,918 shares during the last quarter. Shay Capital LLC raised its stake in Seer by 17.7% in the 3rd quarter. Shay Capital LLC now owns 73,571 shares of the company’s stock valued at $160,000 after acquiring an additional 11,073 shares during the period. Squarepoint Ops LLC raised its stake in Seer by 57.0% in the 3rd quarter. Squarepoint Ops LLC now owns 91,906 shares of the company’s stock valued at $199,000 after acquiring an additional 33,349 shares during the period. Palumbo Wealth Management LLC lifted its holdings in Seer by 22.4% during the third quarter. Palumbo Wealth Management LLC now owns 128,980 shares of the company’s stock valued at $280,000 after purchasing an additional 23,604 shares during the last quarter. Finally, GSA Capital Partners LLP boosted its position in Seer by 31.9% during the third quarter. GSA Capital Partners LLP now owns 246,667 shares of the company’s stock worth $535,000 after purchasing an additional 59,586 shares during the period. 75.20% of the stock is owned by hedge funds and other institutional investors.

Seer Company Profile

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.